-
Mashup Score: 0Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections - 10 month(s) ago
Objective Chronic HBV/HDV infections are a major cause of liver cancer. Current treatments can only rarely eliminate HBV and HDV. Our previously developed preS1-HDAg immunotherapy could induce neutralising antibodies to HBV in vivo and raise HBV/HDV-specific T-cells. Here, we further investigate if a heterologous prime-boost strategy can circumvent T-cell tolerance and preclude HDV superinfection…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 0Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections - 11 month(s) ago
Objective Chronic HBV/HDV infections are a major cause of liver cancer. Current treatments can only rarely eliminate HBV and HDV. Our previously developed preS1-HDAg immunotherapy could induce neutralising antibodies to HBV in vivo and raise HBV/HDV-specific T-cells. Here, we further investigate if a heterologous prime-boost strategy can circumvent T-cell tolerance and preclude HDV superinfection…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
#GUTImage from the paper by Burm et al entitled "Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections" via https://t.co/cWeQWeCxaY #HBV #HDV #LiverTwitter https://t.co/uBYHazEYky
-
-
Mashup Score: 0Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections - 11 month(s) ago
Objective Chronic HBV/HDV infections are a major cause of liver cancer. Current treatments can only rarely eliminate HBV and HDV. Our previously developed preS1-HDAg immunotherapy could induce neutralising antibodies to HBV in vivo and raise HBV/HDV-specific T-cells. Here, we further investigate if a heterologous prime-boost strategy can circumvent T-cell tolerance and preclude HDV superinfection…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
#GUTImage from the paper by Burm et al entitled "Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections" via https://t.co/cWeQWeCxaY #HBV #HDV #LiverTwitter https://t.co/9tGDmDtGJT
-
-
Mashup Score: 1Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections - 11 month(s) ago
Objective Chronic HBV/HDV infections are a major cause of liver cancer. Current treatments can only rarely eliminate HBV and HDV. Our previously developed preS1-HDAg immunotherapy could induce neutralising antibodies to HBV in vivo and raise HBV/HDV-specific T-cells. Here, we further investigate if a heterologous prime-boost strategy can circumvent T-cell tolerance and preclude HDV superinfection…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
#GUTImage from the paper by Burm et al entitled "Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections" via https://t.co/cWeQWeCxaY #HBV #HDV #LiverTwitter https://t.co/J9ldsicfc3
-
-
Mashup Score: 0Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections - 11 month(s) ago
Objective Chronic HBV/HDV infections are a major cause of liver cancer. Current treatments can only rarely eliminate HBV and HDV. Our previously developed preS1-HDAg immunotherapy could induce neutralising antibodies to HBV in vivo and raise HBV/HDV-specific T-cells. Here, we further investigate if a heterologous prime-boost strategy can circumvent T-cell tolerance and preclude HDV superinfection…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
#GUTImage from the paper by Burm et al entitled "Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections" via https://t.co/cWeQWeCxaY #HBV #HDV #LiverTwitter https://t.co/jaolgZOy9g
-
-
Mashup Score: 0D-LIVR topline results: Lonafarnib all-oral, combination regimens boost response in HDV - 1 year(s) ago
Topline findings from the phase 3 D-LIVR trial showed that lonafarnib — boosted with ritonavir and in combination with peginterferon alfa — improved responses in patients with chronic hepatitis D virus, Eiger BioPharmaceuticals announced. Lonafarnib, a first-in-class oral prenylation inhibitor, was granted orphan drug designation by the FDA in 2014 and breakthrough therapy status in
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI D-LIVR topline results: #Lonafarnib all-oral, combination regimens boost response in #HDV @EigerBioPharma1 #GITwitter #LiverTwitter #MedTwitter https://t.co/lHNbgmgEUy
-
-
Mashup Score: 0Care for Patients With Hepatitis D Virus Infection: Expert Guidance for Primary Care Clinicians - 1 year(s) ago
Do you know who you should be screening for hepatitis D infection?
Source: MedscapeCategories: Latest Headlines, PediatricsTweet-
📍 Do you know who you should be screening for #hepatitis D infection? #HDV #MedEd #CME #MedTwitter #Pediatrician 🌐 Developed through a partnership with @ESPCG1. 🖥️ https://t.co/TiT80pXXaN https://t.co/NSgwbI3Do7
-
-
Mashup Score: 0Breakthrough Therapy Bulevirtide was Safe, Effective, and Improved Quality of Life for Hepatitis Patients - 1 year(s) ago
Three posters on the subject were presented at The Liver Meeting and were among the meeting’s key presentation highlights called “Best of the Liver Meeting.”
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
Taken together, this body of research underscores “the clinical utility of #bulevirtide as a potential treatment option for people living with chronic #HDV.” #hepatitis #livertwitter https://t.co/jSjRSjHwhf
-
-
Mashup Score: 0Molecular interactions between hepatitis B virus and delta virus - 2 year(s) ago
As a deficient virus due to the lack of envelope proteins, hepatitis D virus (HDV) causes chronic or fulminant “delta hepatitis” only in people with simultaneous hepatitis B virus (HBV) infection. HBV encodes three types of surface proteins …
Source: PubMed Central (PMC)Categories: Infectious Disease, Latest HeadlinesTweet-
6/ #DeltaHepatitis #HDV One-time screening for HDV in patients with #HBV infection Clinical Pearl: when AST is very elevated but the HBV DNA is not very high - think of HDV coinfection! HDV suppresses HBV reolication! https://t.co/WbGbanYuXm
-
-
Mashup Score: 1
Without approved treatment options for hepatitis D, screening has largely fallen by the wayside; however, promising therapies in phase 3 trials may shift that paradigm, according to a presenter at the GUILD Conference.
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI from @GuildConference: “The reason we should be screening now for delta is that we will have therapeutic alternatives available to us in the very near future,” @norahterrault #HDV #GITwitter #MedTwitter https://t.co/YkRlCunorZ
-
#GUTImage from the paper by Burm et al entitled "Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections" via https://t.co/cWeQWeCxaY #HBV #HDV #LiverTwitter https://t.co/VSSO0debsM